share_log

Evaluating BioNTech: Insights From 12 Financial Analysts

Benzinga ·  Jun 26 20:00

In the preceding three months, 12 analysts have released ratings for BioNTech (NASDAQ:BNTX), presenting a wide array of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings91200
Last 30D10000
1M Ago50000
2M Ago21200
3M Ago10000

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $110.92, along with a high estimate of $122.00 and a low estimate of $98.00. This current average has decreased by 0.61% from the previous average price target of $111.60.

price target chart

Breaking Down Analyst Ratings: A Detailed Examination

A clear picture of BioNTech's perception among financial experts...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment